PDF
ePub
Citation
Print
Abstract
Factor VIII inhibitors are produced during or after coagulation factor VIII (FVIII) therapy in hemophilia A patients. These inhibitors are usually detected by a modified Bethesda assay or an enzyme-linked immunosorbent assay (ELISA). In this study, we used the Bethesda assay to determine the incidence of FVIII inhibitors in 75 fresh plasma samples obtained from 50 hemophilia A patients, and then used ELISA and the Bethesda assay to determine the titres of these inhibitors after the samples had been frozen and thawed. The samples from the screening Bethesda assay were centrifuged and stored at −70°C in accordance with the assay guidelines. Subsequently, these samples were thawed and analyzed using ELISA and the Bethesda assay. The incidence of inhibitors in hemophilia A patients was 20.0%. Among the 35 inhibitor-positive samples identified in the screening Bethesda assay, 16 were positive in ELISA while only 4 were positive in the repeated Bethesda assay. In this study, the ELISA technique showed a higher sensitivity than the Bethesda assay in the detection of FVIII inhibitors in samples that were subjected to freezing and thawing procedures; this was because the Bethesda assay could not identify the FVIII inhibitors that were degraded after freezing and thawing.
REFERENCES
1.Sahud MA., Pratt KP., Zhukov O., Qu K., Thompson AR. ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay. Haemophilia. 2007. 13:317–22.
2.Lindgren A., Wadenvik H., Tengborn L. Characterization of inhibitors to FVIII with an ELISA in congenital and acquired haemophilia A. Haemophilia. 2002. 8:644–8.
3.Clinical and Laboratory Standards Institute. Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays and molecular memostasis assays; approved guideline. CLSI document H21-A5. 5th ed.Wayne, PA: Clinical and Laboratory Standards Institute;2008.
4.National Committee for Clinical Laboratory Standards. Determination of factor VIII coagulant activities; approved guideline. NCCLS document H48-A. Wayne, PA: NCCLS;1997.
5.Verbruggen B., Novakova I., Wessels H., Boezeman J., van den Berg M., Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost. 1995. 73:247–51.
6.Korea Hemophilia Foundation. Korea Hemophilia Foundation 2006. Seoul: Korea Hemophilia Foundation;2007.
7.Hay CR., Brown S., Collins PW., Keeling DM., Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol. 2006. 133:591–605.
8.Ehrenforth S., Kreuz W., Scharrer I., Linde R., Funk M., Gungor T, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet. 1992. 339:594–8.
9.Gringeri A., Mantovani LG., Scalone L., Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood. 2003. 102:2358–63.
10.Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol. 2004. 127:379–91.
11.Moraca RJ., Ragni MV. Acquired anti-FVIII inhibitors in children. Haemophilia. 2002. 8:28–32.
12.Sultan Y. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group. Thromb Haemost. 1992. 67:600–2.
13.Raut S., Heath AB., Barrowcliffe TW. A collaborative study to establish the 6th International Standard for factor VIII concentrate. Thromb Haemost. 2001. 85:1071–8.
14.Winikoff R., Boulanger A., St Louis J., Lacroix S., Rivard GE. An evaluation of the stability of factor VIII inhibitors in plasma and plasma dried on filter paper discs stored at room temperature. Haemophilia. 2003. 9:57–9.
15.Scharrer I., Bray GL., Neutzling O. Incidence of inhibitors in haemophilia A patients: a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia. 1999. 5:145–54.
16.Bray GL., Gomperts ED., Courter S., Gruppo R., Gordon EM., Manco-Johnson M, et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood. 1994. 83:2428–35.
17.Shetty S., Ghosh K., Mohanty D. An ELISA assay for the detection of factor VIII antibodies-comparison with the conventional Bethesda assay in a large cohort of haemophilia samples. Acta Haematol. 2003. 109:18–22.
18.Barthels M., Kraus M., Bohn U., Liese B., von Depka M., Eisert R, et al. Factor VIII inhibitor-tests could be less sensitive than supposed. Vox Sang. 1999. 77(S1):87–9.
19.Sidhu RS., Le T., Brimhall B., Thompson H. Study of coagulation factor activities in apheresed thawed fresh frozen plasma at 1-6°C for five days. J Clin Apher. 2006. 21:224–6.
Table 1.
Results of FVIII antibody detection in the Bethesda screening assay and ELISA
XML Download